Vaccination against SARS-CoV-2 with the drug developed by Moderna produces antibodies against the delta variant, announced this Thursday the biotech company based in Massachusetts, in the United States of America (USA).
Vaccination with Moderna’s covid-19 vaccine produces titers [um teste laboratorial que avalia a concentração] neutralizing against all tested variants, including additional versions of beta (…) and delta variants”, reports a statement released by biotechnology.
According to the note, the vaccine produced by Moderna also produces antibodies against SARS-CoV-2 variants identified in Nigeria, Uganda and Angola.
To conclude the drug’s effectiveness, the statement explains, “samples from eight participants obtained one week” were collected after receiving the second dose.
The analysis revealed “minimal impact in neutralizing titers against the alpha variant” and also “a modest reduction in neutralizing titers against the delta”.
Moderna added that it is developing a strategy to combat “emerging variants”.
Microbiologist João Paulo Gomes said today that the delta variant is 60% more transmissible, is twice as likely to take a person to hospital, but vaccines have proven effective in preventing serious illness.
Speaking to Lusa, the specialist of the National Institute of Health Doctor Ricardo Jorge revealed, through reports made by researchers in the United Kingdom (this variant has a prevalence of 90% in England) and data from the British health authorities that the delta it is 60% more transmissible than the alpha variant (initially known as the UK) and is twice as likely to take the person to hospital, but stresses that the vaccination results “are promising and encouraging”.
With two doses of the vaccine [AstraZeneca], the protection provided against hospitalization is in the order of 92%”, said the expert, adding: “For those who have complete vaccination, this degree of protection against hospitalization is in the order of 92% to 96% [vacina Pfizer], which is excellent”.
The watchword is to vaccinate”, he insisted.
According to the most recent situation report on the genetic diversity of SARS-CoV-2 in Portugal, released by the INSA, the delta variant, initially associated with India, had “a galloping increase” in relative frequency at the national level, passing from 4% in May to 55.6% in June, but its distribution “is still very heterogeneous between regions”.
According to INSA, the distribution of the delta variant varies between 3.2% (Azores) and 94.5% (Alentejo), but, taking into account the trend observed between May and June, “it is expected that this variant will become dominant in the entire national territory during the coming weeks”.
Of the total delta variant sequences analyzed to date, 46 have the additional K417N mutation in the Spike protein, the institute says.
However, he stresses, about 50% of these cases are restricted to just two local transmission chains, which suggests that their community circulation is still limited, with the relative frequency of this profile (Delta+K417N) in the national sample June 2.3%.